冠昊生物(300238) - 2023 Q1 - 季度财报

Revenue and Profitability - Revenue for Q1 2023 was CNY 112.68 million, a decrease of 8.33% compared to CNY 122.93 million in the same period last year[5] - Net profit attributable to shareholders was CNY 22.12 million, an increase of 1.54% from CNY 21.78 million year-on-year[5] - Total operating revenue for Q1 2023 was ¥112,684,910.79, a decrease of 8.5% compared to ¥122,927,958.21 in Q1 2022[16] - Net profit for Q1 2023 increased to ¥24,073,789.17, up 12.7% from ¥21,363,230.14 in Q1 2022[18] - The total comprehensive income for Q1 2023 was ¥25,804,745.59, compared to ¥20,843,673.76 in Q1 2022, indicating a growth of 24%[18] Cash Flow and Financial Position - Net cash flow from operating activities decreased by 65.55% to CNY 8.51 million, down from CNY 24.69 million in Q1 2022, primarily due to reduced sales receipts[8] - The company's cash and cash equivalents decreased by CNY 245,729.79, contrasting with an increase of CNY 17.72 million in Q1 2022[8] - The cash and cash equivalents at the end of Q1 2023 were ¥120,070,051.16, down from ¥177,024,470.99 at the end of Q1 2022[22] - The net cash flow from operating activities was ¥8,507,031.19, down 65.5% from ¥24,690,382.91 in the previous year[21] - The company reported a net cash outflow from investing activities of ¥5,714,848.55, compared to a net outflow of ¥2,369,821.21 in the previous year[21] Assets and Liabilities - Total assets increased by 3.50% to CNY 693.67 million compared to CNY 670.21 million at the end of the previous year[5] - The total assets of Guanhao Biotechnology Co., Ltd. as of the end of Q1 2023 amounted to RMB 693,670,565.52, an increase from RMB 670,209,400.26 at the beginning of the year[14] - The company's current assets increased to RMB 324,503,050.37 from RMB 298,889,385.35, reflecting a growth of approximately 8.5%[14] - The total liabilities decreased slightly to RMB 236,985,727.49 from RMB 239,329,307.83, a reduction of approximately 1.4%[15] - The total equity attributable to the parent company increased to RMB 509,156,430.90 from RMB 485,310,208.77, reflecting a growth of approximately 4.9%[15] Accounts Receivable and Expenses - Accounts receivable increased by 38.39% to CNY 99.60 million, attributed to extended credit terms for high-value clients[7] - Accounts receivable rose significantly to RMB 99,604,610.47, up from RMB 71,975,751.81, indicating an increase of about 38.4%[14] - The company reported a decrease in sales expenses to ¥36,778,009.09 from ¥41,645,417.64, a reduction of 11.5%[16] - The company reported a 61.50% reduction in financial expenses, decreasing to CNY 487,811.41 due to a decrease in loan scale and interest[7] - Research and development expenses remained stable at ¥9,567,734.69, slightly down from ¥9,770,941.24[16] Shareholder Information and Corporate Actions - The number of ordinary shareholders at the end of the reporting period was 29,770, with the largest shareholder holding 20.76% of the shares[9] - The company has received approval for a specific stock issuance to targeted investors, as per the resolutions from the board and shareholder meetings[11] Legal Matters - The company is currently involved in a significant lawsuit, with the case still under trial as of the report date[12]